Prevention of atherosclerosis in patients living with HIV

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 287-300

  De Lorenzo, Ferruccio ^a   Boffito, Marta ^a   Collot Teixeira, Sophie ^b   Gazzard, Brian ^a   McGregor, John L ^b,c   Shotliff, Kevin ^b   Xiao, Han ^d  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Cardiovascular disease; Clinical trial protocol; HIV; Rosuvastatin

Indexed keywords

APOLIPOPROTEIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; ROSUVASTATIN; BIOLOGICAL MARKER; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CAROTID ARTERY DISEASE; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 3 CLINICAL TRIAL; TIME; TREATMENT OUTCOME; VIROLOGY;

ADMINISTRATION, ORAL; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FLUOROBENZENES; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MIDDLE AGED; PYRIMIDINES; RESEARCH DESIGN; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 67449108149     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s5206     Document Type: Article

References (81)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
2. Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the Science Conference. Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS. Executivve summary. Circulation. 2008;118:198-210.
3. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-262.
4. Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest. 2003;111:389-397.
5. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109:1603-1608.
6. Hazenberg MD, Hamann D, Schuitemaker H, et al. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol. 2000;1:285-289.
7. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543.
8. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
9. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356: 1723-1735.
10. Vittecoq D, Escaut L, Chironi G, et al. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS. 2003;17 Suppl 1:S70-S76.
11. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
12. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
13. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
14. Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008;118(2):198-210. Erratum in: Circulation. 2008;118(6):e109.
15. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 2006;7:487-503.
16. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavirritonavir versus lopinavir-ritonavir, each in combination with abacavirlamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial. Lancet. 2006;368:476-482.
17. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506-512.
18. El-Sadr W, Neaton J. Episodic CD4-guided use of ART is inferior to continuous therapy: Results of the SMART Study. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI), 2006; Denver.
19. Klein D, Hurley L, Quesenberry C, et al. Hospitalizations for CHD and MI among Northern California HIV+ and HIV- men: changes in practice and Framingham Risk Scores. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI), 2006; Denver.
20. Moore R, Keruly J. Increasing Incidence of Cardiovascular Disease in HIV-infected Persons in Care. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI), 2003; Boston.
21. Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res. 2000;5:329-333.
22. Available at: http://www.hivforum.org/publications/CVD%20risk% 20aug%2019%20w%20logo.pdf.
23. Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall: A direct measurement with ultrasound imaging. Circulation. 1986;74:1399-1406.
24. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997;146:483-494.
25. Bots ML, Hoes AW, Koudstaal P, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997;96:1432-1437.
26. O'Leary DH, Polak JF, Kronmal RA, et al. for the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14-22.
27. Espeland MA, Craven TA, Riley WA, et al. Reliability of longitudinal ultrasonic measurements of carotid intima-medial thickness. Stroke. 1996;27:480-485.
28. Furberg CD, Adams HP Jr, Applegate WB, et al. for the Asymptomatic Carotid Artery Progression (ACAPS) Study Research Group. Effects of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687.
29. Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS. 2000;14:123-128.
30. Depairon M, Chessex S, Sudre P, et al. with the Swiss HIV Cohort Study. Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS. 2001;15:329-334.
31. Seminari E, Pan A, Voltini G, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis. 2002;162:433-428.
32. Chironi G, Escaut L, Gariepy J, et al. Carotid intima-media thickness in heavily pretreated HIV-infected patients. J Acquir Immune Defic Syndr. 2003;32:490-493.
33. Mercie P, Thiébaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med. 2002;34:55-63.
34. Howard G, Sharrett AR, Heiss G, et al. Carotid artery intimal-media thickness distribution in general populations as evaluated by B-mode ultrasound. Stroke. 1993;24:1297-1304.
35. Aminbakhsh A, Mancini GBJ. Carotid intima-media thickness measurements: what defines an abnormality? A systematic review. Clin Invest Med. 1999;22:149-157.
36. Charakida M, Donald AE, Green H, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation. 2005;112:103-109.
37. Yu CM, Zhang Q, Lam L, et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart. 2007;93:933-939.
38. Crouse JR, 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297:1344-1353.
39. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
40. Crouse JR, 3rd. Thematic review series: patient-oriented research. Imaging atherosclerosis: state of the art. J Lipid Res. 2006;47:1677-1699.
41. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556-1565.
42. Rodriguez-Granillo GA, Agostoni P, Garcia-Garcia HM, et al. Meta-analysis of the studies assessing temporal changes in coronary plaque volume using intravascular ultrasound. Am J Cardiol. 2007;99:5-10.
43. de Groot E, Jukema JW, Montauban van Swijndregt AD, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol. 1998;31:1561-1567.
44. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92:1758-1764.
45. Amarenco P, Labreuche J, Lavallee P, et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date metaanalysis. Stroke. 2004;35:2902-2909.
46. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152-160.
47. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J. 2004;147:705-713.
48. Jones PH, Hunninghake DB, Ferdinand KC, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004;26:1388-1399.
49. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004;116 Suppl 6A:9S-16S.
50. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813-1818.
51. Jialal I, Devaraj S. The role of C-reactive protein activation of nuclear factor kappa-B in the pathogenesis of unstable angina. J Am Coll Cardiol. 2007;49:195-197.
52. Hsue P, Lo J, Franklin A, et al. C-reactive protein levels in patients with HIV: a marker of cardiovascular risk or chronic infection? Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI), 2005; Boston.
53. Henry K, Zackin R, Dube M, et al. ACTG 5056: C-Reactive protein (CRP) levels and cardiovascular risk status for a cohort of HIV-1-infected persons Durably suppressed on an indinavir (IDV)-containing regimen. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI), 2002; Seattle.
54. Noursadeghi M, Miller RF. Clinical value of C-reactive protein measurements in HIV-positive patients. Int J STD AIDS. 2005;16: 438-441.
55. Feldman JG, Goldwasser P, Holman S, et al. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr. 2003;32:210-214.
56. Lau B, Sharrett AR, Kingsley LA, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med. 2006;166:64-70.
57. de Lorenzo F, Feher M, Martin J, et al. Statin therapy-evidence beyond lipid lowering contributing to plaque stability. Curr Med Chem. 2006;13:3385-3393.
58. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4:977-987.
59. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.
60. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109:2818-2825.
61. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet. 1996;347:102-103.
62. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol. 2002;22:1524-1534.
63. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110:285-288.
64. Smith DA, Galin I. Statin therapy for native and peri-interventional coronary heart disease. Curr Mol Med. 2006;6:589-602.
65. Hayden MS, Ghosh S. Signaling to NF-kappa B. Genes Dev. 2004;18:2195-2224.
66. Wong B, Lumma WC, Smith AM, et al. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol. 2001;69:959-62.
67. Feinberg MW, Lin Z, Fisch S, et al. An emerging role for Kruppel-like factors in vascular biology. Trends Cardiovasc Med. 2004;14:241-246.
68. Plutzky J. Peroxisome proliferator-activated receptors as therapeutic targets in inflammation. J Am Coll Cardiol. 2003;42:1764-1766.
69. Lin Z, Kumar A, SenBanerjee S, et al. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res. 2005;96:e48-e57.
70. SenBanerjee S, Lin Z, Atkins GB, et al. KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med. 2004;199:1305-1315.
71. Parmar KM, Nambudiri V, Dai G, et al. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J Biol Chem. 2005;280:26714-26719.
72. Landrier JF, Thomas C, Grober J, et al. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator- activated receptor-alpha-dependent. J Biol Chem. 2004;279: 45512-45518.
73. Zelvyte I, Dominaitiene R, Crisby M, et al. Modulation of inflammatory mediators and PPARgamma and NFkappa B expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res. 2002;45:147-154.
74. JBS 2: Joint British Societies' guidelines on the prevention of cardiovascular disease in clinical practice. Heart. 2005;91 Suppl 5:v1-v52.
75. Van Der Lee M, Vogel M, Schippers E, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI), 2006; Denver.
76. Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47:570-578.
77. Smith J. Much about HIV. BMJ. 2007:334.
78. Taylor AJ, Kent SM, Flaherty AJ, et al. ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol: A randomized trial comparing the effects of aforvastatin and pravastatin on carotid intima media thickness. Circulation. 2002;106: 2055-2060.
79. Smilde TJ, Wollersheim H, van Langen H, et al. Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increase intima-media thickness. Clin Sci (Lond). 1997;93:317-324.
80. Markwood TT, Kents S, Coyle LC, et al. Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol) - a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness. Am Heart J. 2001;141:342-347.
81. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Cirulcation. 1999;100:230-235.